Evaluation of 225Ac-DOTATATE for treatment of lung carcinoid tumors

David Morse, PhD

Year: 2018
Institution: H. Lee Moffitt Cancer Center & Research Institute, Inc
Country: United States
State: FL
Award Type: Pilot
NET Type: Lung
Science Type: Translational


Tirosh and his team will use cutting-edge approaches to characterize the hypoxia-related metabolic drivers to better understand pancreatic NETs (pNETs) and pheochromocytoma development.

What question will the researchers try to answer?

Dr. Tirosh  aims to elucidate whether a false sense of low oxygen levels (pseudohypoxia) in neuroendocrine tumor cells’ microenvironment drives cancer progression. 

Why is this important?

Researchers do not yet fully understand the cause for multiple small intestine NETs and the drivers for developing NETs in other sites in the body, such as the pancreas. 

What will researchers do?

Dr. Tirosh and his team characterized the metabolic compounds (metabolome) generated by the tumor cells and their surrounding tissues. After identifying a compound that may be a cancer-promoting driver, they will now explore the possible mechanism by which it affects the tumor cells’ progression and suppresses the anti-tumoral immune response.

How might this improve the treatment of NETs?

Identifying compounds that drive tumor initiation and progression and understanding how these compounds are being generated may lead to targeted intervention. 

What is the next step?

If Dr. Tirosh’s hypothesis proves correct, they aim to assess the utility of targeted interventions in laboratory NET models, ultimately aiming to add another treatment path for the current management strategies for patients who have NETs.